Home » International News » 2012 » April » April 4, 2012

Octapharma Group Releases 2011 Annual Report

April 4, 2012 - Lachen, Switzerland

2011 has been a successful transitional year for the Octapharma Group. Since octagam® 5% and 10% re-entered all important markets profitability experienced a month-by-month continuous improvement. Re-entry combined with the strong demand for our Haematology and Intensive Care products has led to the successful turnaround of the Octapharma Group in 2011.

Octapharma Group today released figures for the year ending December 31, 2011. Net sales stand at €732 million, which is €14 million or 2% above the 2010 figure. The figures for the last months in 2011 indicate a significant improvement in profitability for 2012. Gross profit in 2011 is €205 million, representing 28% of net sales and an increase of €31 million compared to 2010. Operating expenses are €141 million, €8 million or almost 6% less than in 2010. This includes €43 million investments into Research and Development. Earnings Before Interest and Tax (EBIT) can be reported at €64 million. This reflects a 164% increase compared to 2010.

The promising first months of octagam® returning to the markets allow a positive outlook and it is expected that all key figures will further improve during 2012.

To download the full Octapharma AG 2011 Annual Report click and the Financial section please click here.

About Octapharma AG

Headquartered in Lachen, Switzerland, Octapharma Group is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for almost 30 years. Octapharma’s core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including albumin, immune globulins, coagulation factor and inhibitors. In addition, for more than 20 years Octapharma has manufactured octaplas(LG)® a cell-free pharmaceutical quality therapeutic coagulation-active plasma which has been safeguarded through virus inactivation (S/D treatment) and neutralization of viruses by immune antibodies. Octapharma employs around 4,500 people and has biopharmaceutical experience in more than 80 countries worldwide, including the United States, and operates six state-of-the-art production facilities, of which two sites are licensed by the FDA, providing a high level of production flexibility. For more information, please visit

CONTACTS : Octapharma AG Corporate Communications Corinne Landolt Tel.: +41-(55)-451-21-36

Source: Business Wire India


Comment on this story